Anticoagulation Management

Introduction to Heparin-Induced Thrombocytopenia (HIT)

• Patients on heparin therapy can develop clots due to HIT, which increases thrombosis risk despite anticoagulation, as stated by the American College of Chest Physicians 1
• HIT occurs when heparin exposure leads to formation of IgG antibodies that recognize complexes of platelet factor 4 (PF4) and heparin on platelet surfaces, causing intense platelet activation and thrombin generation, according to the American College of Chest Physicians 1

Pathophysiology and Clinical Presentation

• The pathophysiology of HIT involves binding of antibodies to FcIIa receptors on platelets, leading to intense platelet activation and thrombin generation, as noted by the American College of Chest Physicians 1
• HIT typically occurs 5-10 days after heparin initiation, but can also occur within 24 hours in patients with recent heparin exposure or up to 3 weeks after heparin discontinuation, according to the American College of Chest Physicians 1
• Thrombocytopenia is present in 85-90% of HIT cases, with a platelet count <150 x 10^9/L, as reported by the American College of Chest Physicians 1
• Thrombosis precedes thrombocytopenia in up to 25% of HIT cases, according to the American College of Chest Physicians 1

Risk Factors

• Unfractionated heparin (UFH) carries a 10-fold higher risk of HIT than low-molecular-weight heparin (LMWH), as stated by the American College of Chest Physicians 1
• Higher risk of HIT is observed in cardiac/orthopedic surgery patients (1-5%) compared to medical/obstetric patients (0.1-1%), according to the American College of Chest Physicians 1
• Women have approximately twice the risk of developing HIT compared to men, as reported by the American College of Chest Physicians 1
• The risk of developing HIT varies based on patient factors and type of heparin used, with the following risk levels and clinical scenarios:

Management and Treatment

• When HIT is suspected, alternative non-heparin anticoagulation (such as lepirudin, argatroban, or danaparoid) should be initiated, as recommended by the American College of Chest Physicians 1
• Platelet count monitoring is essential for early detection of HIT, and consider LMWH instead of UFH when appropriate (lower risk of HIT), according to the American College of Chest Physicians 1
• In patients with history of HIT requiring anticoagulation, use non-heparin alternatives, as recommended by the American Society of Hematology 3
• Immediate discontinuation of all heparin products, initiation of alternative non-heparin anticoagulation, avoidance of platelet transfusions unless life-threatening bleeding occurs, and avoidance of warfarin initiation until platelet count recovers to >150,000/mm³, are recommended when HIT is suspected or confirmed, as stated by the American College of Cardiology and the American Society of Hematology 2

Comparison with Inherited Thrombophilias

• Inherited thrombophilias are genetic conditions present from birth, with lifelong duration, and often require long-term anticoagulation, whereas heparin-induced thrombocytopenia is an acquired, immune-mediated drug reaction with temporary duration, according to the American Society of Hematology guidelines 4
• A comparison of inherited thrombophilias and heparin-induced thrombocytopenia is as follows:

Outcomes and Prognosis

• The risk of thrombosis in untreated HIT is approximately five times higher than in treated HIT, according to the American College of Chest Physicians 1
• Recognizing thrombocytopenia early and discontinuing heparin promptly is crucial to prevent thrombotic complications, as stated by the American College of Chest Physicians 1
• Recurrent venous thromboembolism is strongly suggestive of an underlying inherited thrombophilia, as are venous thromboembolism at a young age and a family history of venous thromboembolism, according to the American Heart Association/American Stroke Association guidelines 4